Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

ClinicalTrials.gov ID: NCT03035279

Public ClinicalTrials.gov record NCT03035279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Study identification

NCT ID
NCT03035279
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
AbbVie
Industry
Enrollment
29 participants

Conditions and interventions

Interventions

  • ABBV-181 Drug
  • SC-006 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 7, 2017
Primary completion
Mar 27, 2019
Completion
Mar 27, 2019
Last update posted
Feb 19, 2020

2017 – 2019

United States locations

U.S. sites
9
U.S. states
9
U.S. cities
9
Facility City State ZIP Site status
Highlands Oncology Group /ID# 201182 Fayetteville Arkansas 72703-4005
University of California, Los Angeles /ID# 160882 Los Angeles California 90095
University of Michigan Hospitals /ID# 167101 Ann Arbor Michigan 48109-5008
Mayo Clinic - Rochester /ID# 160884 Rochester Minnesota 55905-0001
Washington University-School of Medicine /ID# 160883 St Louis Missouri 63110
Memorial Sloan Kettering Cancer Center /ID# 160881 New York New York 10065-6007
Carolina BioOncology Institute /ID# 202712 Huntersville North Carolina 28078
Oklahoma University /ID# 202713 Oklahoma City Oklahoma 73104
Tennessee Oncology-Nashville Centennial /ID# 160880 Nashville Tennessee 37203-1632

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03035279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 19, 2020 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03035279 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →